Loading...
Market
Story
Study Finds Batch-Dependent Safety Signal in BNT162b2 Vaccine Using Swedish Data, SAE Rate 1 in 800
Aug 19, 2024, 12:32 PM
A recent study has replicated findings from Danish data using Swedish data, indicating a batch-dependent safety signal for the BNT162b2 vaccine, developed by Pfizer and BioNTech. The study suggests that early commercial batches may have differed from those used later, resulting in more severe adverse events (SAE) in earlier batches, with an SAE rate of 1 in 800. The replication of these findings calls for further investigation into the causes of these differences. Reporting of adverse events, particularly by healthcare professionals, was notably low in Sweden.
View original story
Similar markets
No issues found • 25%
Minor issues found • 25%
Moderate issues found • 25%
Severe issues found • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No changes recommended • 25%
Some vaccines recommended for elimination • 25%
Enhanced safety protocols recommended • 25%
Comprehensive overhaul of vaccine policies • 25%
Yes • 50%
No • 50%
No issues found • 25%
Minor issues found • 25%
Significant issues found • 25%
Undetermined • 25%
Yes • 50%
No • 50%
No change in safety guidelines • 25%
Minor safety warning issued • 25%
Major safety warning issued • 25%
Vaccine approval revoked • 25%
Revised guidelines • 25%
Increased studies • 25%
No change • 25%
Other actions • 25%
CDC • 25%
WHO • 25%
Both • 25%
Neither • 25%